Physician

Rajni Sinha, M.D.

According to 2025 Medicare claims, Rajni Sinha, M.D. (NPI: 1740496850) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fulton, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30318-0922.

Sinha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 460 traditional Medicare patients, billed 69,360 HCPCS/CPT codes, and received $1,289,831 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,632 prescription claims across 312 beneficiaries totaling $4,785,833 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 126 records totaling $141,103. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $73,431 to $1,289,831. Similarly, Part D prescription costs have risen steadily, from $337,058 to $4,785,833. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	284	1,181	$73,431
2016	328	19,140	$317,934
2017	313	48,472	$622,023
2018	439	87,727	$1,230,116
2019	489	131,702	$1,983,787
2020	531	96,222	$2,164,062
2021	460	130,615	$2,145,488
2022	434	108,381	$1,685,600
2023	475	92,799	$1,722,677
2024	460	69,360	$1,289,831

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	137	779	$337,058
2016	151	666	$553,483
2017	149	802	$885,978
2018	170	995	$1,218,499
2019	188	1,384	$2,327,540
2020	222	1,511	$3,625,092
2021	266	1,784	$4,244,338
2022	283	1,818	$3,731,222
2023	303	1,720	$3,980,278
2024	312	1,632	$4,785,833

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	107	$28,325
2016	N/R	16	$9,097
2017	N/R	N/R	N/R
2018	N/R	45	$9,013
2019	N/R	27	$3,706
2020	N/R	54	$5,155
2021	N/R	41	$2,763
2022	N/R	31	$1,324
2023	N/R	11	$1,606
2024	N/R	11	$476

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	54	54	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	160	337	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	281	424	$61
96372	Injection of drug or substance under skin or into muscle	47	161	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	270	622	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	49	1,330	$717,787
Ibrance	Palbociclib	29	812	$460,737
Imbruvica	Ibrutinib	25	700	$404,028
Calquence	Acalabrutinib Maleate	22	660	$320,145
Ninlaro	Ixazomib Citrate	24	672	$311,372

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$476

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	109	$5,573	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$135,529	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rajni Sinha, M.D.?

Tedicare shows public-source Medicare data for Rajni Sinha, M.D. (NPI 1740496850), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rajni Sinha, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rajni Sinha, M.D.?

Rajni Sinha, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Rajni Sinha, M.D. have Open Payments data?

Rajni Sinha, M.D. has 126 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.